Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1953 3
1956 1
1965 1
1981 1
1982 1
1983 3
1985 2
1987 1
1989 2
1990 8
1991 2
1992 5
1993 3
1994 2
1995 1
1996 4
1997 5
1998 4
1999 2
2000 1
2001 5
2002 4
2004 4
2005 4
2006 3
2007 6
2008 1
2009 5
2010 5
2011 2
2012 4
2013 7
2014 2
2015 8
2016 9
2017 6
2018 12
2019 12
2020 14
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

169 results
Results by year
Filters applied: . Clear all Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Del Mastro L, et al. Lancet. 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. Epub 2015 Mar 2. Lancet. 2015. PMID: 25740286 Clinical Trial.
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V. Conte P, et al. Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414. Ann Oncol. 2018. PMID: 30219886 Free article. Clinical Trial.
Pharmacological Characterization of the Microsomal Prostaglandin E(2) Synthase-1 Inhibitor AF3485 In Vitro and In Vivo.
Di Francesco L, Bruno A, Ricciotti E, Tacconelli S, Dovizio M, Guillem-Llobat P, Alisi MA, Garrone B, Coletta I, Mangano G, Milanese C, FitzGerald GA, Patrignani P. Di Francesco L, et al. Front Pharmacol. 2020 Apr 2;11:374. doi: 10.3389/fphar.2020.00374. eCollection 2020. Front Pharmacol. 2020. PMID: 32317963 Free PMC article.
RATIONALE: The development of inhibitors of microsomal prostaglandin (PG)E(2) synthase-1 (mPGES-1) was driven by the promise of attaining antiinflammatory agents with a safe cardiovascular profile because of the possible diversion of the accumulated substrate, PGH(2), towa …
RATIONALE: The development of inhibitors of microsomal prostaglandin (PG)E(2) synthase-1 (mPGES-1) was driven by the promise of attai …
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
AIRTUM Working Group, Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, Bella F, Amodio R, Bizzoco S, Cassetti T, Cirilli C, Cusimano R, De Angelis R, Fusco M, Gatta G, Gennaro V, Giacomin A, Giorgi Rossi P, Mangone L, Mannino S, Rossi S, Pierannunzio D, Tavilla A, Tognazzo S, Tumino R, Vicentini M, Vitale MF, Crocetti E, Dal Maso L. AIRTUM Working Group, et al. Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035. Epidemiol Prev. 2016. PMID: 26951748 Free article.
Knowing the tumour microenvironment to optimise immunotherapy.
Merlano MC, Abbona A, Denaro N, Garrone O. Merlano MC, et al. Acta Otorhinolaryngol Ital. 2019 Feb;39(1):2-8. doi: 10.14639/0392-100X-2481. Acta Otorhinolaryngol Ital. 2019. PMID: 30936573 Free PMC article. Review.
All these elements interact with each other and with conditions related to the tumour (i.e. mutational load, rate of clonal and subclonal mutations) and to host (life style, diet, obesity, age). ...
All these elements interact with each other and with conditions related to the tumour (i.e. mutational load, rate of clonal and subcl …
Ammonia-solvated ammonium species in the NH(4)-ZSM-5 zeolite.
Bonelli B, Armandi M, Areán CO, Garrone E. Bonelli B, et al. Chemphyschem. 2010 Oct 25;11(15):3255-61. doi: 10.1002/cphc.201000477. Chemphyschem. 2010. PMID: 20839270
Since in a previous work (M. Armandi, B. Bonelli, I. Bottero, C. O. Arean, E. Garrone, J. Phys. Chem. C 2010, 114, 6658) the thermodynamic features of the reaction between bare Bronsted acid sites and NH(3) yielding NH(4) (+) species were determined, the data report …
Since in a previous work (M. Armandi, B. Bonelli, I. Bottero, C. O. Arean, E. Garrone, J. Phys. Chem. C 2010, 114, 6658) the t …
Immune-related response criteria: light and shadows.
Merlano M, Occelli M, Garrone O. Merlano M, et al. ESMO Open. 2016 Jul 7;1(4):e000082. doi: 10.1136/esmoopen-2016-000082. eCollection 2016. ESMO Open. 2016. PMID: 27843632 Free PMC article. No abstract available.
Castanea spp. Agrobiodiversity Conservation: Genotype Influence on Chemical and Sensorial Traits of Cultivars Grown on the Same Clonal Rootstock.
Beccaro GL, Donno D, Lione GG, De Biaggi M, Gamba G, Rapalino S, Riondato I, Gonthier P, Mellano MG. Beccaro GL, et al. Foods. 2020 Aug 5;9(8):1062. doi: 10.3390/foods9081062. Foods. 2020. PMID: 32764341 Free PMC article.
Antioxidant capacity ranged from 9.30 0.39 mmol Fe(+2) kg(-1) DW ('Bouche de Betizac') to 19.96 1.89 mmol Fe(+2) kg(-1) DW ('Garrone Rosso'). Monoterpenes represented the main component, reaching 88% for hybrids, followed by polyphenols (10-25% for hybrids and chestnuts, r …
Antioxidant capacity ranged from 9.30 0.39 mmol Fe(+2) kg(-1) DW ('Bouche de Betizac') to 19.96 1.89 mmol Fe(+2) kg(-1) DW ('Garrone
169 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page